Nektar Therapeutics (NKTR)

41.69
NASDAQ : Health Technology
Prev Close 42.62
Day Low/High 40.04 / 43.30
52 Wk Low/High 29.22 / 111.36
Avg Volume 1.90M
Exchange NASDAQ
Shares Outstanding 173.09M
Market Cap 7.38B
EPS -0.60
P/E Ratio 10.32
Div & Yield N.A. (N.A)
How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?

How Will AstraZeneca (AZN) Stock React to FDA's Movantik Approval?

Shares of AstraZeneca (AZN) fell in afternoon trading Tuesday despite the FDA's approval of the constipation drug Movantik, developed by AstraZeneca and and Nektar Therapeutics (NKTR).

Notable Two Hundred Day Moving Average Cross - NKTR

Notable Two Hundred Day Moving Average Cross - NKTR

In trading on Tuesday, shares of Nektar Therapeutics crossed below their 200 day moving average of $11.96, changing hands as low as $11.92 per share. Nektar Therapeutics shares are currently trading down about 2.7% on the day.

First Week of February 2015 Options Trading For Nektar Therapeutics (NKTR)

First Week of February 2015 Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options begin trading this week, for the February 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

First Week of July 19th Options Trading For Nektar Therapeutics (NKTR)

First Week of July 19th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

Why Nektar Therapeutics (NKTR) Stock Is Up Today

Why Nektar Therapeutics (NKTR) Stock Is Up Today

Nektar Therapeutics (NKTR) stock continues to climb following a 'buy' rating by analysts at Jefferies (JEF)

MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO

MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO

Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.

First Week of April 19th Options Trading For Nektar Therapeutics (NKTR)

First Week of April 19th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the April 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new April 19th contracts and identified one put and one call contract of particular interest.

Use Options For A Chance To Buy NKTR At A 42% Discount

Use Options For A Chance To Buy NKTR At A 42% Discount

Looking back to 33 days ago, Nektar Therapeutics priced a 8,500,000 share secondary stock offering at $12.75 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Monday, the stock is now 6.7% above the offering price.

Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock

Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a pre-market mover with heavy volume candidate

Interesting NKTR Put And Call Options For March 22nd

Interesting NKTR Put And Call Options For March 22nd

Investors in Nektar Therapeutics saw new options begin trading this week, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.

First Week of NKTR August 2014 Options Trading

First Week of NKTR August 2014 Options Trading

Investors in Nektar Therapeutics saw new options become available this week, for the August 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Short Interest In Nektar Therapeutics Falls 12.5%

Short Interest In Nektar Therapeutics Falls 12.5%

The most recent short interest data has been released by the NASDAQ for the 09/30/2013 settlement date, which shows a 603,483 share decrease in total short interest for Nektar Therapeutics , to 4,224,171, a decrease of 12.50% since 09/13/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Oversold Conditions For Nektar Therapeutics (NKTR)

Oversold Conditions For Nektar Therapeutics (NKTR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer will be watching Washington and a number of stocks.

First Week Of October 19th Options Trading For Nektar Therapeutics (NKTR)

First Week Of October 19th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

2 Health Care Stocks to Trade for Breakouts

2 Health Care Stocks to Trade for Breakouts

These health care stocks are within range of triggering big breakouts.

Bulls Pile Into Nektar Therapeutics

Bulls Pile Into Nektar Therapeutics

Nektar Therapeutics has been trending higher.

First Week Of NKTR September 21st Options Trading

First Week Of NKTR September 21st Options Trading

Investors in Nektar Therapeutics saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

3 Health Care Stocks Spiking on Big Volume

3 Health Care Stocks Spiking on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Short Interest Drops 20.3% For NKTR

Short Interest Drops 20.3% For NKTR

The most recent short interest data has been released by the NASDAQ for the 05/31/2013 settlement date, which shows a 1,700,119 share decrease in total short interest for Nektar Therapeutics , to 6,690,769, a decrease of 20.26% since 05/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

NKTR Crosses Below Key Moving Average Level

NKTR Crosses Below Key Moving Average Level

In trading on Wednesday, shares of Nektar Therapeutics crossed below their 200 day moving average of $9.06, changing hands as low as $9.05 per share. Nektar Therapeutics shares are currently trading down about 5% on the day.

Nektar Therapeutics Enters Oversold Territory (NKTR)

Nektar Therapeutics Enters Oversold Territory (NKTR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Chaotic Phases Require Patience

Daytrading and overnight flips seem to work best in this algorithm-driven environment, though a few markets show well-organized uptrends.

4 Stocks Under $10 Spiking Higher

4 Stocks Under $10 Spiking Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels

J.P. Morgan Healthcare Confab Live Blog Day Three

J.P. Morgan Healthcare Confab Live Blog Day Three

Live coverage of biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'

A Buysider's Preview of Biotech's Biggest Conference

A Buysider's Preview of Biotech's Biggest Conference

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

TheStreet Quant Rating: D+ (Sell)